Total Assets$XTALPI(02228.HK)SIGX2649 disclosed at AACR2026: globally leading pan-TEAD dual-blocking mechanism, nM-level full-subtype activity, >85% tumor inhibition rate in models such as mesothelioma/liver cancer, excellent safety window. As the second fully differentiated pipeline, it solidifies the replicability of the AI+organoid platform, with IND filings planned for both China and the US in Q2 2026.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
